Skip to main content

Find Clinical Trials

Home
Conditions
Refractory Primary Peritoneal Carcinoma

Clinical trial condition

Refractory Primary Peritoneal Carcinoma

Explore clinical trials studying Refractory Primary Peritoneal Carcinoma. Study availability and eligibility vary by location and protocol.

5 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Refractory Primary Peritoneal Carcinoma trial results

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

NCT04055649

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

Karmanos Cancer Institute at McLaren Flint Flint, Michigan, United States

View Trial Details

Recruiting

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06483048

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +30 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

View Trial Details

Completed

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03026062

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04753216

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations: Northwestern University Chicago, Illinois, United States

View Trial Details

Active, Not Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03907527

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
Locations: National Institutes of Health (NIH) Bethesda, Maryland, United States

Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details